reflux esophagitis associated with systemic scleroderma
Conditions
Interventions
Rabeprazole sodium 1 tablet a day will be added to subjects whose symptom does not improve with 1 tablet a day. The study will continue until subjects meet discontinuance criteria.
Sponsors
Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with systemic sclerosis who have reflux esophagitis diagnosed by upper gastrointestinal endoscopy or esophagus scintigraphy and daily 10mg of oral rabeprazole sodium is not effective for more than two months. Patients who have no malignant lesions in the upper-gastrointestinal tract confirmed by endoscopy. Patients who give written informed consent.
Exclusion criteria
Exclusion criteria: Patients who have a severe difficulty swallowing and who are unable to take orally the tablet. Patients who are judged to be inappropriate as a subject by physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of rabeprazole sodium 20mg against reflux esophagitis associated with systemic scleroderma | — |
Secondary
| Measure | Time frame |
|---|---|
| The safety of rabeprazole sodium 20mg against reflux esophagitis associated with systemic scleroderma | — |
Countries
Japan
Contacts
Public ContactYasuhito Hamaguchi
Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University Dermatology
Outcome results
None listed